Clinical trialNCT04662086CompletedPhase 2Interventional

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

SponsorStanford UniversityEnrollment122Covid19

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization. The overall hypothesis is that through an adaptive trial design, potential effective therapies (single and combination) may be identified for this group of patients. COVID-19 Outpatient Pragmatic Platform Study (COPPS) is a pragmatic platform protocol designed to evaluate COVID-19 treatments by assessing their ability to reduce viral shedding (Viral Domain) or improve clinical outcomes (Clinical Domain). To be included into the platform, every investigational product will collect data for both Domain primary endpoints. Individual treatments to be evaluated in the platform will be described in separate sub-protocols.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Chaitan Khosla, PhD
Stanford University
Principal Investigator
clinicaltrials.gov ↗
Haley Hedlin, PhD
Stanford University
Principal Investigator
clinicaltrials.gov ↗
Manisha Desai, PhD
Stanford University
Principal Investigator
clinicaltrials.gov ↗
Upinder Singh, MD
Stanford University
Principal Investigator
clinicaltrials.gov ↗
Yvonne Maldonado, MD
Stanford University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Valleycare Medical Center
Pleasanton, California, United States
Stanford University
Stanford, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AcebilustatCamostat

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Apr 2021
Primary completion: 3 May 2022
Completion: 2 Feb 2023
Last update posted: 28 Jun 2023
Registered enrollment: 122
Registry id: NCT04662086

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.